|
DIABETES IN CONTROL
|
Kristina
Sandstedt, MS
|
|
 Kristina
Sandstedt,
MS,
Clinical
Exercise
Physiologist,
Diabetes
Educator
“The
Role
of
Exercise
in
the
Treatment
of
Arthritis”,
Why
this
information
is
important
for
Diabetes
Educators
|
|
|
|
Evan
D.
Rosen,
M.D.,
Ph.D
|
|
Dr.
Evan
Rosen
 Winning
the
Battle,
but
Losing
the
War
|
|
|
|
Shafer
Monthly Feature
|
|
 “ANTIOXIDANTS”
Antioxidants
have
received
a
lot
of
attention
in
recent
years,
in
relation
to
wellness
and
disease
prevention.
More
studies
are
needed
to
better
understand
how
antioxidants
may
affect
diabetes
management
and
treatment.
Click
Here
By Sherri Shafer,
R.D., CDE,
View
Sherri's Archives
|
|
|
|
NOMINATE YOUR
CHOICE
|
|
Best
Diabetes
Product
or
Service
of
the
New
Millennium
Medical
Professionals
CHOICE
AWARD
CLICK
HERE
|
|
|
Dr. Eric S. Freedland
|
|
 Dr.
Eric Freedland
continues his series
Why
Focusing On Intensive Glucose Control With Drugs Alone Is
Counterproductive with
Part
10
Manipulating
Macronutrient
Ratios
Eric S. Freedland, MD
|
|
|
|
PRINT
THE NEWSLETTER
|
|
Print this weeks Newsletter Here.
Adobe
format
22
pages
Download
Adobe format
click here.
|
| |
|
|
|
Dr.
Thomas Burke Ph.D
|
-
 Dr
Thomas Burke brings
us a wound care case study by Alan
Kochman, PT, MS and Diane
Pogmore, RN, CWOCN
|
|
|
|
SUBSCRIBE |
|
|
|
|
ADA:
Metformin Decreases Cardiovascular Events in Diabetics
Metformin
monotherapy results in fewer fatal and non-fatal cardiovascular (CV)
events compared to sulfonylurea monotherapy in new users of these
agents.
Said,
investigators said at the 62nd Scientific Sessions of the
American Diabetes Association (ADA).
Dr.
Jeffrey A. Johnson with the University of Alberta in Edmonton, Canada,
and colleagues used Databases of Saskatchewan Health to identify new
users of oral antidiabetic agents, described as those with
prescriptions for a sulfonylurea agent or metformin in 1991 to 1996
who had not used these agents in the prior 12 months.
The
researchers defined CV events as any hospitalization or death during
the follow-up period, which extended up to nine years. Causes of death
or hospitalization were identified based on International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM). They used multivariate logistic regression analysis to
assess the differences between drug cohorts, after adjusting for
potential confounding variables
The
total study sample comprised 8,866 new users of oral antidiabetic
agents with at least one year of drug exposure and no insulin use, who
were followed for an average of 5.3 years.
A
CV-related event occurred in 1,216 of 3,034 (40.1 percent) subjects on
sulfonylurea monotherapy, in 351 of 1,150 (30.5 percent) on metformin
monotherapy, and in 1,733 of 4,682 (37.0 percent) on combination
therapy.
Deaths
due to CV causes were significantly lower in patients treated with
metformin alone or in combination compared to the sulfonyurea
monotherapy cohort.
The
number of non-fatal hospital admissions for CV-related diagnoses was
significantly lower in the metformin monotherapy cohort but the
combination therapy cohort was not significantly different compared to
the sulfonylurea monotherapy group.
The
adjusted odds ratios for a CV-related event were 0.79 and 0.98 for
metformin and combination therapy, respectively, compared to
sulfonylurea monotherapy. .
Dr.
Johnson cautioned that the study is limited by the fact that
information for this analysis was taken from administrative databases
and thus does not contain clinical data.
Another
possible limitation involves the study's retrospective design.
"As with any study using retrospective data, the observations
depend on the accuracy and completeness of the records," Dr.
Johnson said. "However, the Saskatchewan Health databases are
recognized internationally for their accuracy and comprehensiveness of
health care data for all residents of Saskatchewan."
Overall,
observations from this cohort of new users of oral antidiabetic agents
indicate that metformin is safe as either monotherapy or in
combination with sulfonylureas, Dr. Johnson said. In addition, the use
of metformin may be associated with reduced CV mortality in people
with type 2 diabetes.
62nd
Scientific Sessions of the American Diabetes Association (ADA).
[an error occurred while processing this directive]
|
DIABETES NEWS FLASH
|
Dr.
Jennifer Larson
Feature
|
|
Dr
Jennifer Larson, MD,
University
of Nebraska Medical Center, gave
a very informative overview of Pancreas,
Islet, and Kidney Transplantation: Metabolic and Endocrine
Consequences, at the Endo2002 conference. We have an overview
of her presentation, click
here
|
|
|
|
TOP
DIABETES STORIES
|
|
New
Drug Restores Eyesight*
Click
Here
Diabetes
Management Market Predicted to Explode*
Click
Here
Night-Light
May Prevent Diabetic Eye Damage*
Click
Here
New
Test Predicts Which Type 2’s Will Become Type 1’s Within 5 Years*
Click
Here
|
|
|
|
FREE
WEBSITE!!!
|
|
Get
a
FREE
website
for
your
Diabetes
Organization.
Click
Here
To
Learn
More
|
|
NEW PRODUCT
|
|
 400
needles
that
pierce
the
skin
and
let
big
molecules
enter
the
bloodstream.
Drug
delivery
with
this
techniques
offers
several
advantages
over
pills
and
injections.
It
can
ensure
the
steady
release
of
medication
into
the
patient's
bloodstream
over
long
periods,
improving
the
efficacy
of a
dose.
It
can
prevent
the
rapid
breakdown
that
many
drugs
taken
orally
undergo
when
they
pass
through
the
digestive
system.
Click
here
for
more
information:
|
|
|
|
Dr Richard K. Bernstein
|
|
This
Months Corner:
 Dr.
Bernstein's
Feature:
Will
eating a low-fat
diet help you
live longer?
|
|
|
|
INSIDE
DIABETES
|
|
David
Kliff
 The
Pump Market - A
Market in
Turmoil
ADA
Highlights
David
Kliff, Publisher
The Diabetic Investor
|
|
|
|
In
2 Nutrition
|
|
Generate
Individualized meal plans for your patients!
See how your
patients can receive over 250 personalized recipes that are ideal
for individuals with diabetes, high cholesterol, heart disease and
weight management problems.
|
|
|
NEWS
FLASH
!!!
|
|
Over
One
million
US
adults
can't
afford
their
drugs
Click
Here
|
|
|
|
FREE
CME!
|
|
Free
CME
The
Hyperactive
Platelet
in
Type
2
Diabetes-
sponsored
by
Baylor
College
of
Medicine,
Houston,
Texas,
offers
2
hours
of
AMA
PRA
category
1
credit
To
access
this
free
on-line
activity,
visit
Click
Here
|
|
|
|
